Literature DB >> 32102565

Myocardial Ischemia in Children With Anomalous Aortic Origin of a Coronary Artery With Intraseptal Course.

Tam T Doan1, Rodrigo Zea-Vera2, Hitesh Agrawal3, Carlos M Mery4, Prakash Masand1,5, Dana L Reaves-O'Neal1, Cory V Noel1, Athar M Qureshi1, S Kristen Sexson-Tejtel1, Charles D Fraser4, Silvana Molossi1.   

Abstract

BACKGROUND: Intraseptal anomalous aortic origin of a coronary artery is considered a benign condition. However, there have been case reports of patients with myocardial ischemia, arrhythmia, and sudden cardiac death. The purpose of this study was to determine the clinical presentation, myocardial perfusion on provocative stress testing, and management of children with anomalous aortic origin of a coronary artery with an intraseptal course in a prospective cohort.
METHODS: Patients with anomalous aortic origin of a coronary artery and intraseptal course were prospectively enrolled from December 2012 to May 2019, evaluated, and managed following a standardized algorithm. Myocardial perfusion was assessed using stress imaging. Fractional flow reserve was performed in patients with myocardial hypoperfusion on noninvasive testing. Exercise restriction, β-blockers, and surgical intervention were discussed with the families.
RESULTS: Eighteen patients (female 6, 33.3%), who presented with no symptoms (10, 55.6%), nonexertional (4, 22.2%), and exertional symptoms (4, 22.2%), were enrolled at a median age of 12.4 years (0.3-15.9). Perfusion imaging was performed in 14/18 (77.8%) and was abnormal in 7/14 (50%); fractional flow reserve was positive in 5/8 (62.5%). All 4 patients with exertional symptoms and 3/10 (30%) with no or nonexertional symptoms had myocardial hypoperfusion. Coronary artery bypass grafting was performed in a 4-year-old patient; β-blocker and exercise restriction were recommended in 4 patients not suitable for surgery. One patient had nonexertional chest pain and 17 were symptom-free at median follow-up of 2.5 years (0.2-7.1).
CONCLUSIONS: Up to 50% of patients with intraseptal anomalous aortic origin of a coronary artery had inducible myocardial hypoperfusion during noninvasive provocative testing. Long-term follow-up is necessary to understand the natural history of this rare anomaly.

Entities:  

Keywords:  chest pain; coronary artery bypass; fractional flow reserve; myocardial ischemia; perfusion imaging

Year:  2020        PMID: 32102565     DOI: 10.1161/CIRCINTERVENTIONS.119.008375

Source DB:  PubMed          Journal:  Circ Cardiovasc Interv        ISSN: 1941-7640            Impact factor:   6.546


  5 in total

1.  An Atypical Anomalous Aortic Origin of the Left Coronary Artery With Intra-Arterial Wall Course Pretending a Normal Migration on Imaging Screening: A Case Report.

Authors:  Fan Hu; Xinyue Wang; Jiaojiao Wan; Yifei Li; Tao Wang; Kaiyu Zhou; Xiaoqing Shi; Zhongqiang Liu; Jie Fang; Yimin Hua
Journal:  Front Cardiovasc Med       Date:  2022-06-09

2.  Anatomical characteristics of anomalous left coronary artery from the opposite sinus (left-ACAOS) and its clinical relevance: A serial coronary CT angiography study.

Authors:  Pei-Lun Han; Kai-Yue Diao; Shan Huang; Yue Gao; Ying-Kun Guo; Zhi-Gang Yang; Ning Yang
Journal:  Int J Cardiol Heart Vasc       Date:  2020-10-08

Review 3.  Hemodynamic Relevance of Anomalous Coronary Arteries Originating From the Opposite Sinus of Valsalva-In Search of the Evidence.

Authors:  Marius Reto Bigler; Afreed Ashraf; Christian Seiler; Fabien Praz; Yasushi Ueki; Stephan Windecker; Alexander Kadner; Lorenz Räber; Christoph Gräni
Journal:  Front Cardiovasc Med       Date:  2021-01-21

4.  Coronary artery disease in adults with anomalous aortic origin of a coronary artery.

Authors:  Michael X Jiang; Ellen K Brinza; Joanna Ghobrial; Dominique L Tucker; Sohini Gupta; Jeevanantham Rajeswaran; Tara Karamlou
Journal:  JTCVS Open       Date:  2022-04-20

5.  Can we talk? The residual, urgent questions about surgery for coronary artery anomalies.

Authors:  Paolo Angelini; Carlo Uribe
Journal:  JTCVS Open       Date:  2022-04-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.